Nivolumab
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Esophageal Squamous Cell Carcinoma
Conditions
Esophageal Squamous Cell Carcinoma
Trial Timeline
Aug 1, 2019 → Jul 31, 2022
NCT ID
NCT03987815About Nivolumab
Nivolumab is a phase 2 stage product being developed by Ono Pharmaceutical for Esophageal Squamous Cell Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03987815. Target conditions include Esophageal Squamous Cell Carcinoma.
What happened to similar drugs?
19 of 20 similar drugs in Esophageal Squamous Cell Carcinoma were approved
Approved (19) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03987815 | Phase 2 | UNKNOWN |
| NCT03383458 | Phase 3 | Active |
| NCT03090737 | Phase 2 | Completed |
| NCT02857426 | Phase 2 | Completed |
| NCT02743494 | Phase 3 | Completed |
| NCT02632409 | Phase 3 | Active |
| NCT02387996 | Phase 2 | Completed |
Competing Products
20 competing products in Esophageal Squamous Cell Carcinoma